BRIDGEWATER, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Synchronoss Technologies Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a global leader and innovator in Personal Cloud platforms, will hold a conference call on Tuesday, March 11, 2025 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results for the fourth quarter and full year ended December 31, 2024. Financial results will be issued in a press release prior to the call.
Synchronoss management will host the presentation, followed by a question-and-answer period.
Date: Tuesday, March 11, 2025
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-In Number: 877-451-6152 (domestic) or 201-389-0879 (international)
Conference ID: 13751475
The conference call will be broadcast live here and via the Investor Relations section of Synchronoss’ website.
About Synchronoss
Synchronoss Technologies (Nasdaq: SNCR), a global leader in personal Cloud solutions, empowers service providers to establish secure and meaningful connections with their subscribers. Our SaaS Cloud platform simplifies onboarding processes and fosters subscriber engagement, resulting in enhanced revenue streams, reduced expenses, and faster time-to-market. Millions of subscribers trust Synchronoss to safeguard their most cherished memories and important digital content. Explore how our Cloud-focused solutions redefine the way you connect with your digital world at www.synchronoss.com.
Media Relations Contact:
Domenick Cilea
Springboard
dcilea@springboardpr.com
Investor Relations Contact:
Ryan Gardella
ICR for Synchronoss
SNCRIR@icrinc.com
-
“金三银四”装修怎么选中央空调? 看完大金空调再决定随着“金三银四”装修旺季的临近,越来越多的家庭开启了装修计划。家用中央空调作为前置家装的品类之一,是一种需要定制化的系统类产品,其涉及方案配置、安装施工及使2025-02-26
-
Synchronoss Technologies Announces Fourth Quarter and Full Year 2024 Earnings Call DateBRIDGEWATER, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Synchronoss Technologies Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a global lea2025-02-26
-
Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperUZEDY is currently approved in the US as a subcutaneous long-acting injectable (LAI) for use every one or two months for the treatment of schizophre2025-02-26
-
Mavenir 携手 Aira Technologies 助力提升 5G 频谱效率和数据吞吐量展示人工智能驱动的高保真 MIMO 信道估测与预测技术 得克萨斯州理查森和加利福尼亚州萨拉托加, Feb. 26, 2025 (GLOBE NEWSWIRE) -- 作为一家致力于构建未来网2025-02-26
-
The World’s Most Attractive Investment Migration Programs in 2025LONDON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Malta retains 1st place in the 2025 Global Citizenship Program Index for the 10th consecutive year, while2025-02-26